Krishna Das Saha , Ph.D.
Principal Technical Officer
Cancer Biology & Inflammatory Disorder
Research Focus
Inflammatory diseases, Anticancer activity, Nanoparticles, Leishmanial infection
Research Interest
My group is involved in evaluating (a) the disease ameliorating role of several natural and synthetic compounds and of different nanocomposites, (b) Modulation of immunobiological responses in leishmanial infection.
(a) Compounds from herbal and dietary sources, synthetic origins are being examined to
Study the anticancer activity using in vitro and in vivo murine models like melanoma, sarcoma, hepatocarcinoma and colorectal carcinoma
Evaluate their efficacy to improve the disorders of diseases like leishmaniasis, allergic asthma, septicaemia, liver damage, obesity, type I and type II diabetes, and inflammatory bowel disease
Assess anti-oxidant, anti-inflammatory potency of the active compounds
Explore the mechanistic aspects of beneficial effects of the active compounds
Formulate different organ specific improved targeted delivery vehicle of the active compounds/drugs with or without controlled release property
Develop specific targeted therapies of bioactive compounds or drugs combined with specific targeted diagnostics (Theranostics)
Biological evaluation of delivery efficacy of the nanocomposites in vitro and in vivo systems
(b) Leishmanial infection
Krishna Das Saha , Ph.D.
Principal Technical Officer
Cancer Biology & Inflammatory Disorder
Research Focus
Inflammatory diseases, Anticancer activity, Nanoparticles, Leishmanial infection
Research Interest
My group is involved in evaluating (a) the disease ameliorating role of several natural and synthetic compounds and of different nanocomposites, (b) Modulation of immunobiological responses in leishmanial infection.
(a) Compounds from herbal and dietary sources, synthetic origins are being examined to
Study the anticancer activity using in vitro and in vivo murine models like melanoma, sarcoma, hepatocarcinoma and colorectal carcinoma
Evaluate their efficacy to improve the disorders of diseases like leishmaniasis, allergic asthma, septicaemia, liver damage, obesity, type I and type II diabetes, and inflammatory bowel disease
Assess anti-oxidant, anti-inflammatory potency of the active compounds
Explore the mechanistic aspects of beneficial effects of the active compounds
Formulate different organ specific improved targeted delivery vehicle of the active compounds/drugs with or without controlled release property
Develop specific targeted therapies of bioactive compounds or drugs combined with specific targeted diagnostics (Theranostics)
Biological evaluation of delivery efficacy of the nanocomposites in vitro and in vivo systems
(b) Leishmanial infection